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ABSTRACT
Toxic epidermal necrolysis (TEN ) is one of the 
most dramatic and severe adverse cutaneous 
drug reactions. Ciprofloxacin is a frequently 
prescribed fluoroquinolone and can induce TEN  
occasionally. A review of the English literature 
revealed 7 ciprofloxacin-associated TEN  cases 
in the past 10 years. A well-documented fatal 
case of ciprofloxacin induced TEN  is presented. 
This case  report adds to the evidence that 
ciprofloxacin is associated with TEN  in rare 
cases . All healthcare practitioners should be alert 
for signs of TEN  in patients taking ciprofloxacin 
and discontinue the drug immediately. Because 
of the similarity of TEN  to an extensive partial­
thickness burn besides multiorgan involvement 
or complications, transfer of the patient to a burn 
unit in the shortest time is vital.
K ey W o rd s  :  Toxic epidermal necrolysis, 
Ciprofloxacin, Quinolones, Adverse drug 
reactions.
INTRO DUC TION
Toxic epidermal necrolysis (TEN ) or Lyell's 
syndrome is an idiosyncratic severe systemic
disease characterized by extensive full-thickness 
epidermal exfoliation (30-100 %  total body 
surface area), fever, conjunctivitis, and mucous 
membrane involvement (1). TEN  has a 
significant morbidity and high mortality (mean 
30%) with an average incidence of about 1 per 
million persons in Western countries (2).
The most frequent cause for TEN  is drugs, with 
most series showing over 90 % of patients with a 
probable drug cause (3). Antibacterial 
sulfonam ides (cotrim oxazole), aromatic 
anticonvulsants (phénobarbital, phenytoin, 
carbam azepine), some antibiotics
(aminopenicillins, quinolines, cephalosporins), 
some nonsteroidal anti-inflammatory drugs 
(tenoxicam , piroxicam), chlorm ezanone and 
allopurinol were all confirmed as culprit drugs for 
TEN  in a case-control study held in Europe by 
Roujeau et al (4). It is noteworthy that 
corticosteroid use was also associated with the 
development of TEN  in that study.
Nondrug causes of TEN  are uncommon but 
include acute graft-versus-host reaction, 
hepatitis, viral, bacterial and fungal infections. 
Patients with acquired immunodeficiency 
syndrome (AIDS) have a higher incidence of TEN  
(2, 5). Some cases of TEN  have no detectable 
cause (2, 3).
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The exact immunopathologie mechanism of TEN  
is yet to be determined. It is postulated that a 
reactive metabolite produced by alteration in the 
detoxification process complexes with c lass I 
major histocompatibility complex on the 
kératinocyte, causing a cell-mediated immune 
response with cytotoxic T  lymphocytes, and 
cytokines causing kératinocyte damage (3).
A strong association between quinolones and 
TEN  or Stevens-Johnson syndrome (S JS ) has 
been previously reported (4). Seven cases of 
ciprofloxacin-associated TEN  were reported in 
the English literature in the past 10 years (6-11). 
Presented herein is another rare case  of 
ciprofloxacin-induced TEN .
CASE REPORT
A 63-year-old female suffering extensive, full­
thickness epidermal loss was admitted to the 
burn unit. She had first sought medical attention 
20 days prior to admission for urinary infection, 
and she was treated with ciprofloxacin (p.o.500 
mg b.i.d.) on an outpatient basis for 10 days. On 
the tenth day, she presented at the outpatient 
department of another hospital with a two-day 
history of fever, vomiting, and a day history of 
erythema of her face and neck. A tentative 
diagnosis of allergy to the medication was made 
and the drug was discontinued; treatment was 
started with cetrizine dihydrochlorure (p.o.10 mg 
a day). One day after, she presented at the 
emergency department of another hospital with a 
high temperature, irresistible itching, and 
extended maculopapular erythematous rash over 
the trunk. A tentative diagnosis of Stevens- 
Johnson syndrome was made and prednisolone 
(p.o.40 mg b.i.d.) and cefazoline sodium (IV 1 gm
b.i.d.) were initiated. Over the next 5 days, 
erythema and blistering spread to involve almost 
the entire body, sparing only the scalp, and some 
places in the anterior part of the thorax and 
abdomen. It was noted that the skin would peel 
off in sheets with very slight digital pressure 
(Nikolsky’s sign). At this time a diagnosis of toxic 
epidermal necrolysis was made, and she was 
transferred to our burn unit.
On the day of admission the skin resembled a 
recent scald, which covered 95 percent of the 
body surface (F igs. 1 and 2). Her weight was 95
kg and oral temperature w as 38 ,3°C . Physical 
examination revealed bloody, crusted erosions 
over almost the entire body, the perioral region 
and oro-nasal mucosa, sparing only the scalp 
and some places on the anterior part of the 
torso.
A skin biopsy demonstrated full-thickness 
epidermal necrosis. There w as only sparse 
lymphohistiocytic infiltrate, papillary dermal 
edema and dilatation of the dermal vesse ls. 
Focal separation of the epidermis from the 
dermis beneath the basal layer was consistent 
with a diagnosis of toxic epidermal necrolysis.
Laboratory va lues obtained on the day of 
admission showed leukopenia (white blood cell 
count 2 .3 x1 03/pl, reference range 4.4- 
11.3x103/|il), elevated lactate dehydrogenase of 
783 U/l (reference range 0-450 U/l) and, elevated 
liver enzym es (A ST  50 U/l, reference range 5-40 
U/l).
F i g . l  : Extensive skin slough of a  63-year-old woman suffering 
toxic epidermal necrolysis.
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F ' g - 2  :  Face  of the s a m e  patient.
A set of blood and wound cultures drawn early in 
her hospital course grew Methicillin-resistant 
Staphylococcus aureus (M RSA); the patient was 
started on broad-spectrum antibiotic coverage 
including am ikacin (iv 500 mg b .i.d .) and 
vancomycin.(iv 500 mg q.i.d.) and prednisolone 
therapy w as stopped. Each day the wounds were 
covered with chlorhexidine and white petrolatum 
saturated occlusive dressing, following cleaning 
of the wounds in the washing tank. The severe 
conjunctiva inflammation w as treated with 
dexamethasone ophthalmic solution. Eye care 
was provided every 1 to 2 hours and included 
saline rinses. Chest physiotherapy and 
gastrointestinal tube feeding and other 
supportive m easures were begun immediately 
after admission to the burn unit.
The patient’s general condition deteriorated due 
to seps is and other complications of TEN . 
Hemodynamic instability with persistent fever 
developed; pulmonary status worsened, with
decreasing oxygen saturation and a decrease in 
pulmonary compliance requiring increased 
ventilatory support. Although a total of about 8 
L/day fluids were given to the patient and 1.8 
L/day urine output was maintained, the patient 
developed acute renal failure. Urine output 
decreased and blood urea level raised to 161 
mg/dL (reference range 15-44 mg/dL) and total 
bilirubin was 15.4 mg/dL (reference range 0.2-1 
mg/dL). Haemodialysis was attempted but the 
patient expired on the twelfth day after the first 
cutaneous signs appeared and on the fourth day 
of burn unit admission.
DISCUSSION
Fluoroquinolones have been used for 10 years all 
over the world. Ciprofloxacin is one of the most 
prescribed fluoroquinolone. Major adverse 
effects due to ciprofloxacin and other 
fluoroquinolones such as gastrointestinal 
disorders, hypersensitivity reactions, central 
nervous system disorders, hepatic disorders and 
hemolytic disorders were reported (11-14).
There is no reliable test to prove the link between 
a single case of TEN  and a specific drug (15). 
The usefulness of patch tests in TEN  seem s to 
be weak (16). On the other hand, determination 
of a single precipitating factor in drug-related 
TEN  is often difficult, because patients might be 
taking more than one medication. Guillaume et 
al. have utilized an adaptation of the adverse 
drug surveillance system to implicate drugs 
associated with TEN  (17). Under this system 
drugs are assessed for culpability based on the 
following criteria; 1- time interval between drug 
administration and onset of sym ptoms, 2- 
improvement in the patient's condition after 
withdrawal of the drug, 3- disease recurrence 
with re-exposure to the drug, and 4- exclusion of 
other causes of TEN  including other drugs and 
TEN-associated d iseases. The time interval from 
drug administration to bullous eruption is highly 
suggestive of an adverse drug reaction when the 
eruption begins 7-21 days after first 
administration of the drug, or the eruption begins 
within 48 h of administration of the drug if it has 
previously caused a sim ilar reaction in the 
patient. Situations incompatible with adverse 
drug reaction in this case  include: drugs 
administered after the onset of cutaneous or
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mucosal signs, drugs that cause erupi.uiis within 
24 h of administration and cases of lesions 
presenting more than 21 days after first 
administration unless the drug has prolonged 
pharmacokinetics (7, 10, 17). In the presented 
case, the patient was placed on the offending 
drug 8 days before prodrome and early acute 
symptoms began approximately 9 days before 
marked cutaneous manifestations presented. To 
our knowledge this w as the patient’s first 
exposure to ciprofloxacin and hence the time 
period (according to the Guillaum e criteria) 
strongly implicates this fluoroquinolone antibiotic 
as casual for TEN . The patient’s only known 
medical illness was nephrolithiasis . This medical 
condition has not been reported to be associated 
with TEN . Cetrizine dihydrochlorure , cefazoline 
sodium and prednisolone were prescribed after 
the symptoms of the prodrome and the acute 
phase of TEN  had appeared.
Garcia-Doval et al reported that if there is a 
strong suspicion that a patient may have S JS  or 
TEN , prompt withdrawal of drug treatment will 
reduce the risk of death by about 30% per day
(18). In spite of timely cessation of the drug and 
initiation of corticosteroid in our case , the clinical 
picture progressed to TEN  in a few days.
Of the various treatments advocated to modify the 
extent of skin detachment, the one that remains 
the most controversial is the use of systemic 
corticosteroids. Although there is a lack of double­
blind randomized controlled trials that support or 
exclude the benefits of corticosteroids, recent 
data suggest that corticosteroids are more 
detrimental than useful in TEN  and should be 
avoided (2). P lasm apheresis , cyclosporine, 
cyclophosphamide, N-acetylcysteine, monoclonal 
antibodies against cytokines and intravenous 
immunoglobulin have been used in the treatment 
of TEN  but they all need well-controlled clinical 
trials (19, 20).
The main causes of mortality in TEN  are sepsis 
and multiple organ failure, either related to sepsis 
or to adult respiratory distress syndrome besides 
pulmonary, renal and gastrointestinal 
complications (2, 3). The most important 
prognostic factors are the age of the patient, the 
percentage of skin slough, serum urea nitrogen 
level, and viscera l involvement (2). The 
presented patient w as 63 years old, the
percentage of denuded skin was 95, M RSA 
sepsis was developed and serum urea nitrogen 
level was high. These factors were all poor 
prognostic factors. The patient was referred to 
our burn unit 11 days after the onset of 
cutaneous symptoms. Thus she missed the 
opportunity to remove the sloughing skin and to 
apply xenograft, cadaveric skin or other 
biological or synthetic d ressings when the 
wounds were still relatively clean without 
bacterial contam inants. Acute epidermal 
exfoliation seen in TEN  resem bles a partial 
thickness burn and a significant amount of heat 
and fluid can be lost from the denuded skin. If 
viable derm is can be protected from toxic 
detergents, desiccation, mechanical trauma, and 
wound infection, then spontaneous 
epithelialization in 1-3 weeks without scarring is 
the rule (2, 21). The alms of local treatment 
methods used for TEN  are; to minimize heat and 
fluid loss from the wound, to prevent wound 
infection, to reduce pain and to provide moist and 
clean wound environment for promoting re- 
epithelialization. It has been reported that the 
overall rate of bacterem ia, septicem ia, and 
mortality is significantly reduced with early (< 7 
days) referral of TEN  patients to a regional burn 
center (22, 23). Rasm ussen  has developed 
recommendations for hospital management of 
patients with the spectrum of d isease process 
ranging from erythema multiforme minor to toxic 
epidermal necrolysis. He suggests admission to 
a burn center or intensive care unit is appropriate 
when more than 10 %  of the total body surface 
area is blistered or if there is oral or mucosal 
involvement (24).
It is noteworthy that 6 of the 8 patients, who 
developed ciprofloxacin-associated TEN , were 
older than 50 years and all died while the other 2 
young patients survived (6-11). Although TEN  
occurs in all age groups, the incidence of TEN  
increases sharply with age. This increase is 
correlated to the more frequent drug intake in the 
elderly (25, 26).
As a conclusion, ciprofloxacin is associated with 
TEN  in rare cases . All healthcare practitioners 
should be alert for signs of TEN  in patients taking 
ciprofloxacin and discontinue the drug 
immediately. Because of the similarity of TEN  to 
an extensive partial-th ickness burn besides 
multiorgan involvement or complications, transfer
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of the patient to a burn unit in the shortest time is 
vital.
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